Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cofirasersen in mild to moderate COPD with chronic bronchitis
NCT04441788Phase 2Terminated
- Sponsor
- Ionis Pharmaceuticals
- Start
- Dec 2020
- Primary completion
- Apr 2021
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of cofirasersen in chronic obstructive pulmonary disease (COPD) and chronic bronchitis (CB) (3 arms), sponsored by Ionis Pharmaceuticals. Primary endpoint: Forced Expiratory Volume in 1 Second at Week 14. Started Dec 2020; status: terminated.
02
Drugs
cofirasersen
03
Conditions
chronic obstructive pulmonary disease (COPD)chronic bronchitis (CB)
Beyond the preview
Go deeper on NCT04441788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04441788.